SG11201502725TA - Heteroaromatic compounds as pi3 kinase modulators and methods of use - Google Patents
Heteroaromatic compounds as pi3 kinase modulators and methods of useInfo
- Publication number
- SG11201502725TA SG11201502725TA SG11201502725TA SG11201502725TA SG11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- heteroaromatic compounds
- kinase modulators
- modulators
- kinase
- Prior art date
Links
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 150000002390 heteroarenes Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726139P | 2012-11-14 | 2012-11-14 | |
| PCT/US2013/069366 WO2014078211A1 (en) | 2012-11-14 | 2013-11-10 | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502725TA true SG11201502725TA (en) | 2015-05-28 |
Family
ID=50681898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502725TA SG11201502725TA (en) | 2012-11-14 | 2013-11-10 | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9926324B2 (https=) |
| EP (2) | EP3299019B1 (https=) |
| JP (1) | JP6268183B2 (https=) |
| KR (1) | KR102148679B1 (https=) |
| CN (1) | CN104755085B (https=) |
| AU (1) | AU2013345107B2 (https=) |
| BR (1) | BR112015006726B1 (https=) |
| CA (1) | CA2889346C (https=) |
| ES (1) | ES2661380T3 (https=) |
| MY (1) | MY180641A (https=) |
| RU (1) | RU2665036C9 (https=) |
| SG (1) | SG11201502725TA (https=) |
| TW (1) | TWI574962B (https=) |
| WO (1) | WO2014078211A1 (https=) |
| ZA (1) | ZA201502575B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496995A (zh) * | 2014-01-06 | 2015-04-08 | 广东东阳光药业有限公司 | 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法 |
| BR112016029825B1 (pt) * | 2014-06-17 | 2020-10-27 | Cisen Pharmaceutical Co., Ltd. | composto |
| CN105503877A (zh) | 2014-09-24 | 2016-04-20 | 和记黄埔医药（上海）有限公司 | 咪唑并哒嗪类化合物及其用途 |
| AU2015366202B2 (en) * | 2014-12-19 | 2020-01-02 | Janssen Pharmaceutica Nv | Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors |
| MA41174B1 (fr) | 2014-12-19 | 2019-09-30 | Janssen Pharmaceutica Nv | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta |
| DK3472160T3 (da) * | 2016-06-16 | 2021-05-10 | Janssen Pharmaceutica Nv | Bicykliske pyridin-, pyrazin- og pyrimidinderivater som pi3k-beta-inhibitorer |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF |
| DK3548033T3 (da) * | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| CN108164525B (zh) * | 2016-12-08 | 2020-09-08 | 沈阳药科大学 | 一种抗肿瘤化合物的制备方法和用途 |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| FR3064364A1 (fr) * | 2017-03-27 | 2018-09-28 | S.P.C.M. Sa | Methode de dosage de polymeres cationiques |
| AU2021263914A1 (en) | 2020-04-29 | 2022-11-03 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| US20250090540A1 (en) * | 2021-09-10 | 2025-03-20 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| WO2023220131A2 (en) * | 2022-05-10 | 2023-11-16 | Relay Therapeutics, Inc. | PI3Kα INHIBITORS AND METHODS OF USE THEREOF |
| CN120737113B (zh) * | 2025-09-03 | 2025-11-21 | 湖北师范大学 | 一种三唑并哒嗪类化合物区域选择性c3-h炔基化的方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2036924C1 (ru) * | 1989-01-31 | 1995-06-09 | Такеда Кемикал Индастриз ЛТД | Способ получения производных имидазо (1,2-b)пиридазина или их солей и производные имидазо (1,2-b)пиридазина или их соли |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| AU1061395A (en) | 1993-11-30 | 1995-06-19 | Mcgill University | Inhibition of dna methyltransferase |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6268137B1 (en) | 1996-05-22 | 2001-07-31 | Methylgene, Inc. | Specific inhibitors of DNA methyl transferase |
| US6020318A (en) | 1997-05-30 | 2000-02-01 | Methylgene, Inc. | DNA methyltransferase genomic sequences and antisense oligonucleotides |
| AU8125098A (en) | 1997-05-30 | 1998-12-30 | Mcgill University | Dna methyltransferase genomic sequences and antisense oligonucleotides |
| US6066625A (en) | 1998-02-03 | 2000-05-23 | Methylgene, Inc. | Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
| US6953783B1 (en) | 1998-10-19 | 2005-10-11 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
| JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
| KR20020070285A (ko) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
| EP2093292A2 (en) | 2000-03-24 | 2009-08-26 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
| AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6723733B2 (en) * | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP2006503082A (ja) | 2002-10-17 | 2006-01-26 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| KR101153335B1 (ko) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| KR101257343B1 (ko) | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| SI2495016T1 (sl) | 2005-12-23 | 2020-04-30 | Ariad Pharmaceuticals, Inc. | Biciklične heteroarilne spojine |
| RU2009107705A (ru) * | 2006-08-04 | 2010-09-10 | Такеда Фармасьютикал Компани Лимитед (Jp) | Конденсированное гетероциклическое соединение и его применение |
| JP2010539239A (ja) * | 2007-09-17 | 2010-12-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体 |
| US20100311736A1 (en) | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
| AU2008343813B2 (en) * | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| ES2392482T3 (es) * | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| AR071523A1 (es) * | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| CA2799579A1 (en) * | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US8637516B2 (en) * | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| AU2012257513B2 (en) | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| WO2012174312A2 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
| KR101274986B1 (ko) | 2011-07-27 | 2013-06-17 | 한국과학기술원 | 이미다조피리딘 유도체, 이를 포함하는 ＰＩ3Ｋ 및/또는 ｍＴＯＲ 저해제용 약학 조성물 및 ＰＩ3Ｋ 및/또는 ｍＴＯＲ과 연관된 질환 치료용 약학 조성물 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
-
2013
- 2013-11-08 TW TW102140742A patent/TWI574962B/zh active
- 2013-11-10 CA CA2889346A patent/CA2889346C/en active Active
- 2013-11-10 AU AU2013345107A patent/AU2013345107B2/en active Active
- 2013-11-10 RU RU2015116102A patent/RU2665036C9/ru active
- 2013-11-10 BR BR112015006726-3A patent/BR112015006726B1/pt not_active IP Right Cessation
- 2013-11-10 JP JP2015541973A patent/JP6268183B2/ja active Active
- 2013-11-10 ES ES13855522.2T patent/ES2661380T3/es active Active
- 2013-11-10 US US14/076,256 patent/US9926324B2/en active Active
- 2013-11-10 CN CN201380054625.XA patent/CN104755085B/zh active Active
- 2013-11-10 EP EP17192050.7A patent/EP3299019B1/en active Active
- 2013-11-10 KR KR1020157008264A patent/KR102148679B1/ko active Active
- 2013-11-10 EP EP13855522.2A patent/EP2919784B1/en active Active
- 2013-11-10 WO PCT/US2013/069366 patent/WO2014078211A1/en not_active Ceased
- 2013-11-10 MY MYPI2015701411A patent/MY180641A/en unknown
- 2013-11-10 SG SG11201502725TA patent/SG11201502725TA/en unknown
-
2015
- 2015-04-16 ZA ZA2015/02575A patent/ZA201502575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102148679B1 (ko) | 2020-08-27 |
| BR112015006726B1 (pt) | 2021-11-23 |
| WO2014078211A1 (en) | 2014-05-22 |
| EP2919784A4 (en) | 2016-07-06 |
| EP2919784A1 (en) | 2015-09-23 |
| EP2919784B1 (en) | 2017-12-20 |
| CA2889346C (en) | 2018-09-25 |
| EP3299019B1 (en) | 2019-10-09 |
| EP3299019A1 (en) | 2018-03-28 |
| RU2665036C2 (ru) | 2018-08-27 |
| HK1210956A1 (en) | 2016-05-13 |
| JP2015536994A (ja) | 2015-12-24 |
| AU2013345107B2 (en) | 2016-02-25 |
| ES2661380T3 (es) | 2018-03-28 |
| TWI574962B (zh) | 2017-03-21 |
| ZA201502575B (en) | 2016-11-30 |
| AU2013345107A1 (en) | 2015-04-30 |
| MY180641A (en) | 2020-12-04 |
| CA2889346A1 (en) | 2014-05-22 |
| TW201422615A (zh) | 2014-06-16 |
| RU2665036C9 (ru) | 2018-11-12 |
| BR112015006726A2 (pt) | 2017-08-22 |
| RU2015116102A (ru) | 2017-01-10 |
| CN104755085B (zh) | 2018-05-01 |
| CN104755085A (zh) | 2015-07-01 |
| JP6268183B2 (ja) | 2018-01-24 |
| US20140134133A1 (en) | 2014-05-15 |
| US9926324B2 (en) | 2018-03-27 |
| KR20150083833A (ko) | 2015-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201502575B (en) | Heteroaromatic compounds as pi3 kinase modulators and methods of use | |
| SG11201405131XA (en) | Dll3 modulators and methods of use | |
| ZA201503134B (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| SG11201504049VA (en) | Compounds and their methods of use | |
| AU2013203459A1 (en) | DLL3 modulators and methods of use | |
| SG11201600028YA (en) | Substituted aminopyrimidine compounds and methods of use | |
| PT2815769T (pt) | Fam19a5 para utilização no diagnóstico e tratamento de lesões do snc | |
| ZA201405253B (en) | Heterocyclic compounds and methods for their use | |
| SG11201505493QA (en) | Heteroaromatic compounds as pi3 kinase modulators | |
| ZA201405257B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| EP3019477A4 (en) | Heterocyclic compounds and methods of their use | |
| IL244268A0 (en) | Heterocyclic compounds and methods of use | |
| AP2014007979A0 (en) | Heterocyclic compounds and their uses | |
| ZA201408856B (en) | Heteroaryl compounds and methods of use thereof | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| AU2012900650A0 (en) | Compounds and methods of their use | |
| AU2012900651A0 (en) | Compounds and methods of their use |